Phthaleinsulfathiazole

In commercial-scale oral solid dosage (OSD) manufacturing, phthaleinsulfathiazole is processed as a low-micron active pharmaceutical ingredient (API) with a typical particle size distribution where D₉₀ ≤ 100 µm is targeted to ensure content uniformity in direct compression blends. Granular product recovered from synthesis trains is routinely milled through a cone mill fitted with a 0.5 mm rasp screen and subsequently classified via vibratory sieving; over-size fractions are re-milled in a pin mill operating at a tip speed of 65–85 m/s to avoid excessive amorphous content, which has been correlated with accelerated hydrolytic degradation in the presence of moisture. Pre-formulation compatibility screening using isothermal microcalorimetry confirms that the compound is incompatible with strong alkaline excipients (pH > 8.5) and with primary amines found in certain disintegrants, leading to a restriction that crospovidone-based superdisintegrants must be limited to ≤ 2.0% w/w of the core tablet mass, while croscarmellose sodium is substituted at 3.0–5.0% to achieve a disintegration time under 3 minutes when tested per USP <701>.

Blending uniformity is monitored through stratified sampling at 10 locations across a 600 L bin blender rotating at 12 rpm for 15–20 minutes; the acceptance criterion is a relative standard deviation (RSD) of ≤ 5.0% for the API assay determined by a validated HPLC method with UV detection at 258 nm. The lubricant, magnesium stearate, is added at 0.75% w/w and blended for an additional 3 minutes; extended lubrication beyond 5 minutes has been shown to increase ejection force on a 16-station rotary tablet press from 150 N to 380 N, accompanied by a reduction in tensile strength of the compacted tablets by 18–22% due to shear-induced coating of API particles. Tablets are compressed to a target hardness of 6–8 kp (USP <1217>) using B-tooling on a press running at 45–55 rpm, and weight variation is controlled to ± 3.0% for a theoretical weight of 400 mg per tablet. Any formulation path that incorporates wet granulation is subject to a rigorous risk assessment: the API undergoes significant polymorphic shift from Form I to Form II when the granulating fluid exceeds 18% w/w water and the wet mass is exposed to temperatures above 45 °C for more than 2 hours during fluid-bed drying. To mitigate this, low-moisture granulation with isopropyl alcohol (5–8% w/w of the dry blend) is preferred, or aqueous granulation is performed with a strict inlet air temperature of 55 ± 3 °C and a product temperature ceiling of 42 °C, confirmed by in-line NIR probes monitoring the characteristic absorbance band at 1920 nm.

Compliance standards: ICH Q7 GMP for active pharmaceutical ingredients; USP monograph for Phthaleinsulfathiazole (current edition); Ph. Eur. monograph 0362; FDA 21 CFR Part 211; testing per USP <905> Uniformity of Dosage Units and USP <711> Dissolution (Apparatus 2, 50 rpm, 900 mL of pH 6.8 phosphate buffer). Addition rate: API loading in immediate-release tablets ranges from 55% to 68% w/w, typically corresponding to a 500 mg labeled dose per unit. End-product forms: Immediate-release uncoated tablets, film-coated tablets with HPMC-based coatings (weight gain 2.5–3.5%), and capsule-filled powder blends where the capsule shell is gelatin or HPMC. Published data on continuous direct compression with this specific API is limited; batch manufacturing remains the dominant mode based on field reports from contract manufacturing organizations.

What drives the sedimentation instability in reconstituted oral suspensions containing this sulfonamide?

Suspension concentrates and dry syrups for reconstitution present a distinct set of formulation hurdles because the API, with a true density of approximately 1.52 g/cm³ and a plate-like crystal habit, settles rapidly in vehicles with a viscosity below 150 mPa·s at 25 °C. Production-scale compounding vessels with a capacity of 1000 L are charged with a structured vehicle consisting of microcrystalline cellulose/carboxymethylcellulose sodium co-processed suspending agent at 1.8–2.4% w/w and xanthan gum at 0.15–0.25% w/w; the yield stress of the final vehicle must exceed 0.8 Pa to arrest sedimentation of the API particles during a 72-hour accelerated settling study at 40 °C. Upon re-dispersion, the suspension must deliver a uniform dose with a pour-out recovery of ≥ 95% of the labeled amount when measured according to USP <698>.

The manufacturing process follows a sequence where the API is first dispersed in a high-shear rotor-stator mixer at 3000 rpm for 10 minutes in a pre-mix containing a wetting agent such as polysorbate 80 at 0.3% w/w, enabling adequate de-agglomeration without generating foam that would interfere with subsequent vacuum de-aeration at −0.08 MPa. The suspension is then combined with the fully hydrated suspending medium and homogenized in an in-line high-pressure homogenizer operating at 150–200 bar to reduce the median particle size to D₅₀ ≤ 25 µm; a second pass may be required if the initial particle size distribution exceeds D₉₀ = 70 µm. Critical process parameters include the temperature of the homogenization stage, which must be kept below 35 °C by a jacket cooling system, as localized thermal spikes have been correlated with a 4–6% increase in total related substances within 6 months of storage at 30 °C/65% RH. Preservative efficacy testing per USP <51> mandates the inclusion of sodium benzoate at 0.2% w/w and potassium sorbate at 0.1% w/w, with a target pH of 5.5–6.5.

Compliance standards: WHO Technical Report Series, No. 1010 (Annex 2) on liquid preparations for oral use; EMA Guideline on pharmaceutical development of medicines for paediatric use; CFR 21 Part 211.110 sampling and testing of in-process materials. Addition rate: The API concentration in reconstituted suspension is set at 100 mg/mL or 250 mg/mL, translating to 10–25% w/v; the dry powder for reconstitution contains API at 85–90% w/w with the remainder being suspending agents, sweeteners, and preservatives. End-product forms: Amber glass bottles (150 mL or 200 mL) with a child-resistant closure and a graduated oral dosing syringe; dry syrup powder in single-dose sachets laminated with aluminum foil to achieve a moisture vapor transmission rate below 0.001 g/m²·day.

Premix uniformity challenges in medicated feed incorporating phthaleinsulfathiazole at sub-therapeutic to therapeutic inclusion levels

Veterinary premix manufacturing for swine and poultry species exploits the compound’s bacteriostatic activity against Escherichia coli and Salmonella spp., with the primary objective being a homogeneous distribution of the API at concentrations as low as 100 mg/kg in final feed. Starting with a concentrated intermediate premix containing 10–20% w/w API on a calcium carbonate or ground corn cob carrier, the process employs a ribbon blender of 600–1000 L working volume with a fill level of 60–70% and a mixing time of 8–12 minutes at 20–25 rpm; the coefficient of variation (CV) for 10 thief samples taken post-mixing must be below 7.0% when assayed by a UV spectrophotometric method at 260 nm. Carrier selection is not trivial: porous carriers with a bulk density mismatch greater than 30% relative to the API lead to segregation during subsequent pneumatic conveying to the bagging station, a problem frequently observed when the premix is transported over distances exceeding 20 meters at a conveying velocity of 15–20 m/s.

Stability in the presence of common feed ingredients dictates several exclusion rules. Chloride salts added as electrolytes in poultry drinking water or feed supplements accelerate hydrolytic cleavage of the sulfonamide bond when the water activity in the premix exceeds 0.6, a condition typical in molasses-based carriers; therefore, molasses is explicitly prohibited. Furthermore, the addition of organic acids commonly used as feed preservatives (propionic acid, formic acid) must be physically separated from the premix granule, as contact at a localized pH below 3.5 irreversibly precipitates degradation products exceeding the 0.5% unspecified impurity threshold defined in VICH GL11. The premix is packed in multi-wall paper bags with a polyethylene inner liner, and the recommended shelf life is 18 months at 25 °C and 60% RH.

Compliance standards: VICH GL18 (residual solvents in veterinary medicinal products); EU Regulation 2019/4 on medicated feed; FDA 21 CFR Part 558 (new animal drugs for use in animal feeds); USP General Chapter <905> adapted for premix uniformity. Addition rate: Premix concentration is standardized at 100 g/kg, 200 g/kg, or 500 g/kg API, diluted in final feed to 100–400 g/ton for swine and 200–500 g/ton for poultry, depending on the veterinarian-prescribed regimen. End-product forms: Type A medicated article (concentrated premix) supplied in 25 kg bags; Type B medicated feed intermediate; Type C medicated finished feed produced by mixing the premix into a complete ration.

When the drinking water route is preferred over in-feed delivery for mass medication of flocks

Soluble powder formulations intended for administration via drinking water systems demand a completely different physical form specification than premixes: the API must achieve complete dissolution or stable colloidal dispersion in hard water with a total hardness of up to 300 ppm as CaCO₃ within 2 minutes of stirring at 200 rpm. This necessitates a solid dispersion manufacturing approach in which phthaleinsulfathiazole is co-micronized with a hydrophilic carrier, typically glucose monohydrate or anhydrous citric acid, in a fluidized-bed opposed jet mill with a classifier set to a cut-point of 15 µm. The resulting co-processed powder, containing API at 80–85% w/w, is filled into hermetically sealed laminated foil pouches under nitrogen atmosphere with a residual oxygen headspace concentration below 2.0%, as oxidative degradation has been documented to accelerate above this threshold at tropical storage conditions of 40 °C/75% RH.

Field experience with commercial drinking water proportioners (Dosatron, Inject-o-Matic) reveals that the wetted parts of the dosing pump must be composed of 316 stainless steel or PVDF, as prolonged contact of the sulfonamide solution with brass or copper fittings results in a 15–20% reduction in delivered dose over a 24-hour medication period due to metal-chelate complexation. The final medicated water is prepared at a target concentration of 500 mg/L to 1000 mg/L, and stock solution stability is not to exceed 8 hours at ambient temperature (22–25 °C); after this window, microbial proliferation and photolytic degradation become significant, with a recorded 6–8% drop in assay value in uncovered tanks exposed to direct sunlight. Prophylactic cleaning protocols for the water lines include flushing with 0.1% hydrogen peroxide solution post-medication to remove biofilm that may otherwise adsorb residual API and create sub-inhibitory exposure conditions favoring resistance development.

Compliance standards: EMA/CVMP 793/04 on stability testing of veterinary medicinal products; CFR 21 Part 520 (oral dosage form new animal drugs); EPA drinking water guidance for livestock (when applicable). Addition rate: Soluble powder is reconstituted directly to yield 500 mg/L or 1000 mg/L of active in the drinking line; the powder itself is 80–85% w/w API with the remainder consisting of a solubilizing carrier and an anti-caking agent such as silicon dioxide at 0.5% w/w. End-product forms: Single-use 100 g or 500 g laminated foil pouches; bulk presentation in 5 kg foil-lined drums for large poultry integrations; the reconstituted solution is never packaged as a finished product but prepared on-site immediately before administration.

Reference standard qualification and the analytical lifecycle of phthaleinsulfathiazole in compendial and contract testing environments

The compound is routinely distributed as a pharmaceutical secondary standard, traceable to USP or Ph. Eur. reference materials, for use in pharmacopoeial assay and purity tests. Certification of a batch as a reference standard involves a multi-lab collaborative study following ISO 17034 and ISO/IEC 17025 protocols, where the assigned purity is determined by mass balance subtracting the sum of impurities measured by HPLC with diode array detection, residual solvents by headspace GC-FID per USP <467>, water content by Karl Fischer titration per USP <921> Method 1a, and residue on ignition per USP <281>. The combined uncertainty budget must not exceed ± 0.5% at the 95% confidence level. During column screening for the related substances method, stationary phases with a high silanol activity index amplify peak tailing for the sulfonamide analyte; a base-deactivated C18 column (4.6 × 250 mm, 5 µm) with a carbon load of 14–16% is selected, and the mobile phase consists of acetonitrile:pH 3.0 phosphate buffer (25:75 v/v) pumped at 1.2 mL/min with a column temperature of 30 °C.

Long-term stability of the reference standard stored in a desiccator at 20 ± 2 °C is monitored through re-qualification every 12 months, with a documented decline in purity of < 0.05% per year provided the container remains unopened and is protected from light. Once the container is opened, the in-use period is set at 4 weeks to limit hygroscopic moisture uptake, which in a controlled study reached 0.3% w/w after 48 hours of exposure at 60% RH. The material is also used for system suitability testing during dissolution method transfer; a standard solution of 50 µg/mL in dissolution medium (pH 6.8 buffer) is injected 6 times, and the RSD of the peak area must be ≤ 2.0%. Any batch failing the suitability criteria is traced back to the vacuum oven drying step, where a temperature deviation above 105 °C during drying for loss-on-drying determination (105 °C, 2 hours) artificially lowers the assigned purity due to thermal degradation on the analytical balance pan.

Compliance standards: USP <11> USP Reference Standards; Ph. Eur. General Chapter 5.12; ISO 17034:2016; ICH Q2(R2) for method validation parameters (specificity, linearity, accuracy, precision). Addition rate: Not applicable in a formulation sense; typical vial fill is 200 mg or 500 mg of neat API. End-product forms: Amber glass vials with a PTFE-lined screw cap containing 200 mg or 500 mg of certified reference standard; sealed under argon. Also available as a 1.0 mg/mL solution in methanol in flame-sealed ampoules for single-use calibration.

Co-formulated sachets for eradication of bacterial enteritis in swine: blending constraints and packaging barrier selection

A specialized veterinary dosage form combines phthaleinsulfathiazole with a potentiator such as sulfadimidine at a fixed ratio of 1:1 or 1:0.5 in a powder sachet designed for direct oral administration to piglets. The two actives exhibit vastly different compaction and flow properties: phthaleinsulfathiazole has a Hausner ratio of 1.35–1.45, placing it in the “cohesive” classification, while sulfadimidine flows freely with a Hausner ratio below 1.15. To prevent segregation during the sachet filling operation on a vertical form-fill-seal machine running at 60 cycles/min, the actives are granulated together via a dry granulation route using a roller compactor with a roll pressure of 8–12 kN/cm and a roll gap of 1.5–2.0 mm, followed by milling to a uniform granule size fraction of 150–710 µm. The resulting granules are filled into sachets at a target fill weight of 10.0 g ± 3%, and seal integrity is verified by a vacuum decay method capable of detecting a leak channel equivalent to a 15 µm capillary.

The choice of laminate structure for the sachet is driven by the oxygen sensitivity already described; a three-layer structure of 12 µm polyester / 9 µm aluminum foil / 50 µm low-density polyethylene is specified, achieving an oxygen transmission rate below 0.005 cc/m²·day·atm and a water vapor transmission rate below 0.01 g/m²·day. Pharmacokinetic rationale for the fixed-dose ratio derives from elimination half-life differences: phthaleinsulfathiazole is poorly absorbed from the gastrointestinal tract and exerts its action locally, whereas sulfadimidine is partially absorbed and contributes to systemic activity; this dual action is meaningful only when the formulation guarantees intact co-transit of both molecules into the lower jejunum, a requirement that fails if the blend separates during storage and handling on the farm. A worst-case stability study performed with sachets stored inverted at 40 °C/75% RH for 6 months shows that the ratio of the two actives deviates by less than 1.5% from the label claim when the granule integrity is maintained.

Compliance standards: WHO Good Manufacturing Practices for veterinary pharmaceutical products; VICH GL3 stability testing; EMA Guideline on fixed-dose combination veterinary medicinal products (EMA/CVMP/ 742/13). Addition rate: The combined API content in the sachet powder is 60–75% w/w, with the split between the two sulfonamides depending on the target indication. End-product forms: Laminated foil sachets of 5 g, 10 g, or 20 g filled with dry granules; each sachet constitutes a single dose for an individual animal or a small group, administered by mixing with milk replacer or feed gruel.